Dianthus Therapeutics DNTH Operating Income
Operating Income at other companies
Other financials
Where this comes from
Reported directly by Dianthus Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:OperatingIncomeLoss.
The official record: Dianthus Therapeutics’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Dianthus Therapeutics's operating income.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Dianthus Therapeutics's operating income?
- Dianthus Therapeutics (DNTH) reported operating income of -$46.53M in Q1 2026.
- How has Dianthus Therapeutics's operating income changed year-over-year?
- Dianthus Therapeutics's operating income decreased by 40.3% year-over-year, from -$33.18M to -$46.53M.
- What is the long-term trend for Dianthus Therapeutics's operating income?
- Over 3 years (2021 to 2024), Dianthus Therapeutics's operating income has grown at a 10.9% compound annual growth rate (CAGR), from -$74.69M to -$101.86M.
- What does operating income mean?
- Gross profit minus all operating expenses (SG&A, R&D, D&A). Measures the profit from core business operations before interest, taxes, and non-operating items.